by admin | Feb 12, 2018 | In the News
Low Tolerance for Pain? The Reason May Be In Your Genes Apr 21, 2014, 15:15 ET from American Academy of Neurology...
by admin | Feb 12, 2018 | Press Releases
(PRWEB) APRIL 07, 2015 Proove Biosciences a commercial and research leader in Personalized Medicine, is excited to announce the launch of Proove Opioid Response – the world’s first clinical laboratory test to predict responders to opioid pain medications....
by admin | Feb 12, 2018 | In the News
The new Proove Non-Opioid Pain Medication Response profile evaluates genetic factors to predict a patient’s response to non opioids before prescribing Irvine, CA (PRWEB) – Proove Biosciences, a commercial and research leader in Personalized Medicine, is excited...
by admin | Feb 12, 2018 | In the News
Irvine, CA (PRWEB) July 14, 2015 Proove Biosciences, a commercial and research leader in Personalized Medicine, recently presented data on three ground-breaking scientific studies at the Neurological Disorders Summit in San Francisco, CA. The Neurological Disorders...
by admin | Feb 12, 2018 | Press Releases
Proove Biosciences, a commercial and research leader in personalized medicine, is excited to announce their partnership with the Keck Medicine of the University of Southern California(USC) Pain Center to study the genetics of chronic pain. The T.R.O.J.A.N. Study...
Recent Comments